Pereira Miriam Salles, Cardoso Liana Monteiro da Fonseca, da Silva Tatiane Barreto, Teixeira Ayla Josma, Mizrahi Saul Eliahú, Ferreira Gabriel Schonwandt Mendes, Dantas Fabio Moyses Lins, Cotta-de-Almeida Vinicius, Alves Luiz Anastacio
Laboratory of Cellular Communication, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, 4365 Manguinhos, Rio de Janeiro 21045-900, Brazil.
Volta Redonda University Center-UniFOA, Av. Paulo Erlei Alves Abrantes, 1325-Três Poços, Volta Redonda 27240-560, Brazil.
Materials (Basel). 2020 Nov 11;13(22):5090. doi: 10.3390/ma13225090.
Microencapsulation is a widely studied cell therapy and tissue bioengineering technique, since it is capable of creating an immune-privileged site, protecting encapsulated cells from the host immune system. Several polymers have been tested, but sodium alginate is in widespread use for cell encapsulation applications, due to its low toxicity and easy manipulation. Different cell encapsulation methods have been described in the literature using pressure differences or electrostatic changes with high cost commercial devices (about 30,000 US dollars). Herein, a low-cost device (about 100 US dollars) that can be created by commercial syringes or 3D printer devices has been developed. The capsules, whose diameter is around 500 µm and can decrease or increase according to the pressure applied to the system, is able to maintain cells viable and functional. The hydrogel porosity of the capsule indicates that the immune system is not capable of destroying host cells, demonstrating that new studies can be developed for cell therapy at low cost with microencapsulation production. This device may aid pre-clinical and clinical projects in low- and middle-income countries and is lined up with open source equipment devices.
微囊化是一种被广泛研究的细胞治疗和组织生物工程技术,因为它能够创建一个免疫特权位点,保护被包裹的细胞免受宿主免疫系统的攻击。已经测试了几种聚合物,但海藻酸钠因其低毒性和易于操作而广泛用于细胞封装应用。文献中描述了使用压差或静电变化的不同细胞封装方法,这些方法需要使用高成本的商业设备(约30,000美元)。在此,已经开发出一种可以由商业注射器或3D打印设备制造的低成本设备(约100美元)。这些胶囊的直径约为500微米,并且可以根据施加到系统的压力而减小或增大,能够维持细胞的活力和功能。胶囊的水凝胶孔隙率表明免疫系统无法破坏宿主细胞,这表明可以开展新的研究,以低成本通过微囊化生产进行细胞治疗。该设备可能有助于低收入和中等收入国家的临床前和临床项目,并且与开源设备相一致。